Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B) submitted its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, covering the month ended 31 May 2026.

The company’s authorised share capital remained unchanged at RMB 243.42 million, comprising 235.70 million H shares and 7.71 million unlisted foreign shares, all with a par value of RMB 1.

Issued share capital was also stable. As at 31 May 2026, BIOHEART-B had 235.70 million issued H shares and 7.71 million unlisted foreign shares; no treasury shares were outstanding, and there were no share allotments, cancellations or repurchases during the month.

Management confirmed that the H-share public float continued to meet the Main Board’s 25% minimum threshold.

The return indicated no outstanding share options, warrants, convertible securities or other agreements that could dilute equity. The document was signed by Executive Director and Joint Company Secretary Wang Yuqing.